← 프로그램 목록
ADCPhase 3Recruiting

Cyclin-Dependent Kinase 4 Inhibitor

SWOG Cancer Research Network

비교

Cyclin-Dependent Kinase 4 Inhibitor(SWOG Cancer Research Network)은 HER2 표적 ADC로, Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: TArgeting Chimera (PROTAC) estrogen receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 19.2% (ClinicalTrials.gov NCT02499146). 차별점: first-in-class, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

HER2

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)

oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CC

deruxtecan (T-DXd) and tyrosine kinase inhibitors

lentiviral knockdown experiments

humanized xenograft model and showed no evidence of significant off-target toxicity in immunocompetent hosts

first-in-class, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader

Mechanism of Action

TArgeting Chimera (PROTAC) estrogen receptor

T-cell-inflamed microenvironment by providing a sustained chemotactic signal CCL5 for CD8+ T cell recruitment

apoptosis, associated with increased mRNA levels of positive regulators of cell cycle gene Cyclin E and proliferating cell nuclea

biomarker, Cyclin-dependent kinase 4 inhibitor A (p16INK4a)

resistance to ET, particularly caused by ESR1 mutations, has not been fully addressed

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 50건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2 · Phase 1, Phase 2
  • Status: Completed · Not yet recruiting · Active, not recruiting
  • 주요 endpoint: Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast Cancer · Real-World Progression Free Survival (rwPFS) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer · Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer · Real-World Response Rate (rwTR) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer · Number of Participants According to Initial Dose of Palbociclib: Palbociclib + Aromatase Inhibitor Arm Only
  • 등록된 결과: ORR 19.2%
  • 핵심: As part of the global clinical development program for Palbociclib, studies are planned in cancer patients in China. An …

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Cyclin-Dependent Kinase 4 Inhibitor은 어떤 치료제인가요?
Cyclin-Dependent Kinase 4 Inhibitor(SWOG Cancer Research Network)은 HER2 표적 ADC로, Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Cyclin-Dependent Kinase 4 Inhibitor의 임상 단계는?
Cyclin-Dependent Kinase 4 Inhibitor의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.